Mucin-Phenotype and Expression of the Protein V-Set and Immunoglobulin Domain Containing 1 (VSIG1): New Insights into Gastric Carcinogenesis
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Ho, S.W.T.; Tan, P. Dissection of gastric cancer heterogeneity for precision oncology. Cancer Sci. 2019, 110, 3405–3414. [Google Scholar] [CrossRef]
- Chia, N.-Y.; Tan, P. Molecular classification of gastric cancer. Ann. Oncol. 2016, 27, 763–769. [Google Scholar] [CrossRef]
- Laurén, P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and so-called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol. Microbiol. Scand. 1965, 64, 31–49. [Google Scholar] [CrossRef]
- Xiao, L.-J.; Zhao, S.; Zhao, E.-H.; Zheng, X.; Gou, W.-F.; Xing, Y.-N.; Takano, Y.; Zheng, H.-C. Clinicopathological and prognostic significance of MUC-2, MUC-4 and MUC-5AC expression in japanese gastric carcinomas. Asian Pac. J. Cancer Prev. 2012, 13, 6447–6453. [Google Scholar] [CrossRef]
- Javanbakht, M.; Akhavanmoghadam, J.; Talaei, A.J.; Aghyani, M.; Mozafari, M.; Khedmat, L.; Mohebbi, M. Differential expression of two genes Oct-4 and MUC5AC associates with poor outcome in patients with gastric cancer. Clin. Exp. Pharmacol. Physiol. 2017, 44, 1099–1105. [Google Scholar] [CrossRef]
- Kim, S.M.; Kwon, C.H.; Shin, N.; Park, D.Y.; Moon, H.J.; Kim, G.H.; Jeon, T.Y. Decreased Muc5AC expression is associated with poor prognosis in gastric cancer. Int. J. Cancer 2013, 134, 114–124. [Google Scholar] [CrossRef]
- Sriamornsak, P.; Wattanakorn, N.; Takeuchi, H. Study on the mucoadhesion mechanism of pectin by atomic force microscopy and mucin-particle method. Carbohydr. Polym. 2010, 79, 54–59. [Google Scholar] [CrossRef]
- Crater, J.S.; Carrier, R.L. Barrier Properties of Gastrointestinal Mucus to Nanoparticle Transport. Macromol. Biosci. 2010, 10, 1473–1483. [Google Scholar] [CrossRef]
- Figueiras, A.; Vieira, A.; Simoes, S.; Veiga, F. Mucoadhesive Buccal Systems as a Novel Strategy for Anti-Inflammatory Drugs Administration. Anti-Inflamm. Anti-Allergy Agents Med. Chem. 2012, 10, 190–202. [Google Scholar] [CrossRef]
- Santos-Silva, F.; Fonseca, A.; Caffrey, T.; Carvalho, F.; Mesquita, P.; Reis, C.; Almeida, R.; David, L.; Hollingsworth, M.A. Thomsen-Friedenreich antigen expression in gastric carcinomas is associated with MUC1 mucin VNTR polymorphism. Glycobiology 2005, 15, 511–517. [Google Scholar] [CrossRef]
- Pinto-De-Sousa, J.; David, L.; Reis, C.; Gomes, R.; Silva, L.; Pimenta, A. Mucins MUC1, MUC2, MUC5AC and MUC6 expression in the evaluation of differentiation and clinico-biological behaviour of gastric carcinoma. Virchows Arch. 2002, 440, 304–310. [Google Scholar] [CrossRef]
- Mozgovoĭ, S.I.; Livzan, M.A.; Predvechnaia, I.K.; Kononov, A.V. Proliferative and mucin-producing activities in the foci of intestinal meta-plasia associated with chronic atrophic gastritis and gastric ulcer. Vestn. Ross. Akad. Meditsinskikh Nauk. 2010, 7, 15–18. [Google Scholar]
- Kocer, B.; Ulas, M.; Ustundag, Y.; Erdogan, S.; Karabeyoglu, M.; Yldrm, O.; Unal, B.; Cengiz, O.; Soran, A. A Confirmatory Report for the Close Interaction of Helicobacter pylori With Gastric Epithelial MUC5AC Expression. J. Clin. Gastroenterol. 2004, 38, 496–502. [Google Scholar] [CrossRef]
- Chen, Y.; Pan, K.; Li, S.; Xia, J.; Wang, W.; Chen, J.; Zhao, J.; Lü, L.; Wang, D.; Pan, Q.; et al. Decreased expression of V-set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer. J. Surg. Oncol. 2012, 106, 286–293. [Google Scholar] [CrossRef]
- Inoue, Y.; Matsuura, S.; Yoshimura, K.; Iwashita, Y.; Kahyo, T.; Kawase, A.; Tanahashi, M.; Maeda, M.; Ogawa, H.; Inui, N.; et al. Characterization of V-set and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells. Cancer Sci. 2017, 108, 1701–1714. [Google Scholar] [CrossRef]
- Chandrashekar, D.S.; Bashel, B.; Balasubramanya, S.A.H.; Creighton, C.J.; Ponce-Rodriguez, I.; Chakravarthi, B.V.S.K.; Varambally, S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017, 19, 649–658. [Google Scholar] [CrossRef]
- Chang, L.; Zhou, G.; Soufan, O.; Xia, J. miRNet 2.0: Network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Res. 2020, 48, W244–W251. [Google Scholar] [CrossRef]
- Machlowska, J.; Baj, J.; Sitarz, M.; Maciejewski, R.; Sitarz, R. Ganstric cancer: Epidemiology, risk factors, classification, genomic characteristics, and treatment strategies. Int. J. Mol. Sci. 2020, 21, 4012. [Google Scholar] [CrossRef]
- Yusefi, A.R.; Lankarani, K.B.; Bastani, P.; Radinmanesh, M.; Kavosi, Z. Risk Factors for Gastric Cancer: A Systematic Review. Asian Pac. J. Cancer Prev. 2018, 19, 591–603. [Google Scholar] [CrossRef]
- Tatematsu, M.; Tsukamoto, T.; Inada, K. Stem cells and gastric cancer: Role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci. 2003, 94, 135–141. [Google Scholar] [CrossRef]
- Kawachi, T.; Kogure, K.; Tanaka, N.; Tokunaga, A.; Sugimura, T. Studies of intestinal metaplasia in the gastric mucosa by detection of disaccharidases with “Tes-Tape”. J. Natl. Cancer Inst. 1974, 53, 19–30. [Google Scholar] [CrossRef]
- Kim, D.H.; Shin, N.; Kim, G.H.; Song, G.A.; Jeon, T.-Y.; Kim, D.-H.; Lauwers, G.Y.; Park, D.Y. Mucin Expression in Gastric Cancer: Reappraisal of Its Clinicopathologic and Prognostic Significance. Arch. Pathol. Lab. Med. 2013, 137, 1047–1053. [Google Scholar] [CrossRef]
- Saad, R.S.; Ghorab, Z.; Khalifa, M.A.; Xu, M. CDX2 as a marker for intestinal differentiation: Its utility and limitations. World J. Gastrointest. Surg. 2011, 3, 159–166. [Google Scholar] [CrossRef]
- Satala, C.-B.; Jung, I.; Kovacs, Z.; Staden, R.-I.S.-V.; Molnar, C.; Bara, T.; Patrichi, A.-I.; Gurzu, S. V-set and immunoglobulin domain containing 1 (VSIG1) as an emerging target for epithelial–mesenchymal transition of gastric cancer. Sci. Rep. 2022, 12, 16241. [Google Scholar] [CrossRef]
- VSIG1 V-Set and Immunoglobulin Domain Containing 1 [Homo Sapiens (Human)]—Gene—NCBI. Available online: https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=340547 (accessed on 28 December 2022).
- Scanlan, M.J.; Ritter, G.; Yin, B.W.T.; Williams, C.; Cohen, L.S.; Coplan, K.A.; Fortunato, S.R.; Frosina, D.; Lee, S.-Y.; Murray, A.E.; et al. Glycoprotein A34, a novel target for antibody-based cancer immunotherapy. Cancer Immun. 2006, 6, 2. [Google Scholar]
- Kim, J.H.; Kim, K.-J.; Rhee, Y.-Y.; Bae, J.M.; Cho, N.-Y.; Lee, H.S.; Kang, G.H. Gastric-type expression signature in serrated pathway–associated colorectal tumors. Hum. Pathol. 2015, 46, 643–656. [Google Scholar] [CrossRef]
- Oidovsambuu, O.; Nyamsuren, G.; Liu, S.; Göring, W.; Engel, W.; Adham, I.M. Adhesion Protein VSIG1 Is Required for the Proper Differentiation of Glandular Gastric Epithelia. PLoS ONE 2011, 6, e25908. [Google Scholar] [CrossRef]
- Gurzu, S.; Sugimura, H.; Szederjesi, J.; Szodorai, R.; Braicu, C.; Kobori, L.; Fodor, D.; Jung, I. Interaction between cadherins, vimentin, and V-set and immunoglobulin domain containing 1 in gastric-type hepatocellular carcinoma. Histochem. Cell Biol. 2021, 156, 377–390. [Google Scholar] [CrossRef]
- Kende, A.I.; Carr, N.J.; Sobin, L.H. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. Histopathology 2003, 42, 137–140. [Google Scholar] [CrossRef]
- Gulmann, C.; Counihan, I.; Grace, A.; Patchett, S.; Leen, E.; Leader, M.; Kay, E. Cytokeratin 7/20 and mucin expression patterns in oesophageal, cardia and distal gastric adenocarcinomas. Histopathology 2003, 43, 453–461. [Google Scholar] [CrossRef] [PubMed]
- Marín, F.; Bonet, C.; Muñoz, X.; García, N.; Pardo, M.L.; Ruiz-Liso, J.M.; Alonso, P.; Capellà, G.; Sanz-Anquela, J.M.; González, C.A.; et al. Genetic variation in MUC1, MUC2 and MUC6 genes and evolution of gastric cancer precursor lesions in a long-term follow-up in a high-risk area in Spain. Carcinogenesis 2012, 5, 1072–1080. [Google Scholar] [CrossRef] [PubMed]
- Sokolova, O.; Naumann, M. NF-κB Signaling in Gastric Cancer. Toxins 2017, 9, 119. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.-H.; Zheng, J.-B.; Qi, J.; Yang, K.; Wu, Y.-H.; Wang, K.; Wang, C.-B.; Sun, X.-J. Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway. Int. J. Oncol. 2019, 54, 879–892. [Google Scholar] [CrossRef] [PubMed]
- Kolell, K.J.; Crawford, D.L. Evolution of Sp Transcription Factors. Mol. Biol. Evol. 2002, 19, 216–222. [Google Scholar] [CrossRef] [PubMed]
- Yu, Y.; Peng, K.; Li, H.; Zhuang, R.; Wang, Y.; Li, W.; Yu, S.; Liang, L.; Xu, X.; Liu, T. SP1 upregulated FoxO3a promotes tumor progression in colorectal cancer. Oncol. Rep. 2018, 39, 2235–2242. [Google Scholar] [CrossRef] [PubMed]
- Hu, L.; Chen, Q.; Wang, Y.; Zhang, N.; Meng, P.; Liu, T.; Bu, Y. Sp1 Mediates the Constitutive Expression and Repression of the PDSS2 Gene in Lung Cancer Cells. Genes 2019, 10, 977. [Google Scholar] [CrossRef]
- Liu, Y.; Du, Y.; Hu, X.; Zhao, L.; Xia, W. Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer. BMC Cancer 2018, 18, 367. [Google Scholar] [CrossRef]
- Vellingiri, B.; Iyer, M.; Subramaniam, M.D.; Jayaramayya, K.; Siama, Z.; Giridharan, B.; Narayanasamy, A.; Dayem, A.A.; Cho, S.-G. Understanding the Role of the Transcription Factor Sp1 in Ovarian Cancer: From Theory to Practice. Int. J. Mol. Sci. 2020, 21, 1153. [Google Scholar] [CrossRef]
- Shi, S.; Zhang, Z. Role of Sp1 expression in gastric cancer: A meta-analysis and bioinformatics analysis. Oncol. Lett. 2019, 18, 4126–4135. [Google Scholar] [CrossRef]
- Cai, Y.; Yi, M.; Chen, D.; Liu, J.; Guleng, B.; Ren, J.; Shi, H. Trefoil factor family 2 expression inhibits gastric cancer cell growth and invasion in vitro via interactions with the transcription factor Sp3. Int. J. Mol. Med. 2016, 38, 1474–1480. [Google Scholar] [CrossRef]
- Jiang, W.; Jin, Z.; Zhou, F.; Cui, J.; Wang, L.; Wang, L. High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients. Surg. Oncol. 2015, 24, 220–225. [Google Scholar] [CrossRef] [PubMed]
- Gurzu, S.; Kadar, Z.; Sugimura, H.; Orlowska, J.; Bara, T.; Szederjesi, J.; Jung, I. Maspin-related Orchestration of Aggressiveness of Gastric Cancer. Appl. Immunohistochem. Mol. Morphol. 2016, 24, 326–336. [Google Scholar] [CrossRef] [PubMed]
- Nagtegaal, I.D.; Odze, R.D.; Klimstra, D.; Paradis, V.; Rugge, M.; Schirmacher, P.; Washington, K.M.; Carneiro, F.; Cree, I.A.; the WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020, 76, 182–188. [Google Scholar] [CrossRef]
- Gurzu, S.; Sugimura, H.; Orlowska, J.; Szederjesi, J.; Szentirmay, Z.; Bara, T.; Fetyko, A.; Jung, I. Proposal of a Dukes-Mac-Like Staging System for Gastric Cancer. J. Investig. Med. 2017, 65, 316–322. [Google Scholar] [CrossRef] [PubMed]
Parameter | Intestinal Metaplasia (n = 16) | Without Metaplasia (n = 44) | p-Value | |
---|---|---|---|---|
Sex | Male | 31.25% (5) | 95.45% (42) | <0.0001 |
Female | 68.75% (11) | 4.55% (2) | ||
Age (years) | <60 | 62.5% (10) | 13.63% (6) | 0.001 |
≥60 | 37.5% (6) | 86.37% (38) | ||
Histologic Grade | G2 | 43.75% (7) | 45.45% (20) | 0.906 |
G3 | 56.25% (9) | 54.55% (24) | ||
Tumor Stage | pT1-2 | 18.75% (3) | 13.63% (6) | 0.727 |
pT3 | 31.25% (5) | 25% (11) | ||
pT4 | 50% (8) | 61.37% (27) | ||
Dukes-MAC-like Stage | A-B | 12.5% (2) | 11.36% (5) | 0.865 |
C | 31.25 (5) | 25% (11) | ||
D | 56.25% (9) | 63.64% (28) | ||
Surgical Margins | Positive (R1/R2) | 18.75% (3) | 20.45% (9) | 0.883 |
Negative (R0) | 81.25% (13) | 79.55% (35) | ||
Lymphatic Invasion | Present (L1) | 62.5% (10) | 68.18% (30) | 0.679 |
Absent (L0) | 37.5% (6) | 31.82% (14) | ||
Blood Vessel Invasion | Present (V1) | 43.75% (7) | 54.55% (24) | 0.459 |
Absent (V0) | 56.25% (9) | 45.45% (20) | ||
Lymph Node Metastases | Present (N1+) | 87.5% (14) | 79.55% (35) | 0.481 |
Absent (N0) | 12.5% (2) | 20.45% (9) | ||
Distant Metastases | Present (M1) | 25% (4) | 18.18% (8) | 0.559 |
Absent (M0) | 75% (12) | 81.82% (36) |
Parameter | MUC2 Positive (n = 11) | MUC2 Negative (n = 49) | p-Value | MUC5AC Positive (n = 20) | MUC5AC Negative (n = 40) | p-Value | CDX2 Positive (n = 21) | CDX2 Negative (n = 39) | p-Value | |
---|---|---|---|---|---|---|---|---|---|---|
Sex | Male | 27.27% (3) | 89.8% (44) | <0.0001 | 70% (14) | 82.5% (33) | 0.267 | 47.62% (10) | 94.88% (37) | 0.0002 |
Female | 72.73% (8) | 10.2% (5) | 30% (6) | 17.5% (7) | 52.38% (11) | 5.12% (2) | ||||
Age (years) | <60 | 36.36% (4) | 24.5% (12) | 0.42 | 40% (8) | 20% (8) | 0.098 | 33.33% (7) | 23.07% (9) | 0.391 |
≥60 | 63.64% (7) | 75.5% (37) | 60% (12) | 80% (32) | 66.67% (14) | 76.93% (30) | ||||
Histologic Grade | G2 | 45.45% (5) | 44.9% (22) | 0.973 | 35% (7) | 50% (20) | 0.27 | 71.42% (15) | 30.76% (12) | 0.002 |
G3 | 54.55% (6) | 55.1% (27) | 65% (13) | 50% (20) | 28.58% (6) | 69.26% (27) | ||||
Tumor Stage | pT1-2 | 18.18% (2) | 14.28% (7) | 0.771 | 15% (3) | 15% (6) | 0.011 | 33.33% (7) | 5.12% (2) | 0.001 |
pT3 | 18.18% (2) | 28.56% (14) | 50% (10) | 15% (6) | 38.09% (8) | 20.51% (8) | ||||
pT4 | 63.64% (7) | 57.16% (28) | 35% (7) | 70% (28) | 28.58% (6) | 74.37% (29) | ||||
Dukes-MAC-like Stage | A-B | 27.27% (3) | 8.16% (4) | 0.183 | 20% (4) | 7.5% (3) | 0.14 | 14.28% (3) | 10.24% (4) | 0.018 |
C | 27.27% (3) | 26.54% (13) | 35% (7) | 22.5% (9) | 4.76% (1) | 38.46% (15) | ||||
D | 45.45% (5) | 65.3% (32) | 45% (9) | 70% (28) | 80.96% (17) | 51.3% (20) | ||||
Surgical Margins | R1/2 | 72.73% (8) | 8.16% (4) | <0.0001 | 35% (7) | 12.5% (5) | 0.039 | 52.38% (11) | 2.56% (1) | <0.0001 |
R0 | 27.27% (3) | 91.84% (45) | 65% (13) | 87.5% (35) | 47.62% (10) | 97.44% (38) | ||||
Lymphatic Invasion | L1 | 27.27% (3) | 75.5% (37) | 0.002 | 50% (10) | 75% (30) | 0.052 | 61.91% (13) | 69.24% (27) | 0.565 |
L0 | 72.73% (8) | 24.5% (12) | 50% (10) | 25% (10) | 38.09% (8) | 30.76% (12) | ||||
Blood Vessel Invasion | V1 | 45.45% (5) | 53.06% (26) | 0.648 | 55% (11) | 50% (20) | 0.714 | 47.62% (10) | 76.92% (30) | 0.021 |
V0 | 54.55% (6) | 46.94% (23) | 45% (9) | 50% (20) | 52.38% (11) | 23.08% (9) | ||||
Lymph Node Metastases | N1+ | 90.9% (10) | 79.6% (39) | 0.38 | 85% (17) | 80% (32) | 0.637 | 71.42% (15) | 81.17% (34) | 0.132 |
N0 | 9.1% (1) | 20.4% (10) | 15% (3) | 20% (8) | 28.58% (6) | 12.83% (5) | ||||
Distant Metastases | M1 | 63.64% (7) | 10.2% (5) | 0.0006 | 40% (8) | 10% (4) | 0.006 | 28.58% (6) | 15.38% (6) | 0.223 |
M0 | 36.36% (4) | 89.8% (44) | 60% (12) | 90% (36) | 71.42% (15) | 84.62% (33) |
Parameter | VSIG1 Negative (n = 47) | VSIG1 Positive (n = 13) | p-Values | |
---|---|---|---|---|
Sex | Male | 78.72% (37) | 76.92% (10) | 0.754 |
Female | 21.28% (10) | 23.08% (3) | ||
Age (years) | <60 | 17.02% (8) | 61.53% (8) | 0.034 |
≥60 | 82.98% (39) | 38.47% (5) | ||
Histologic Grade | G2 | 44.68% (21) | 46.15% (6) | 0.924 |
G3 | 55.32% (26) | 53.85% (7) | ||
Tumor Stage | pT1-2 | 10.63% (5) | 30.76% (4) | 0.165 |
pT3 | 29.78% (14) | 15.38% (2) | ||
pT4 | 59.59% (28) | 53.85% (7) | ||
Dukes-MAC-like Stage | A-B | 6.38% (3) | 30.76% (4) | 0.046 |
C | 29.78% (14) | 15.38% (2) | ||
D | 63.82% (30) | 53.85% (7) | ||
Surgical Margins | R1/2 | 19.14% (9) | 23.08% (3) | 0.754 |
R0 | 80.86% (38) | 76.92% (10) | ||
Lymphatic Invasion | L1 | 65.95% (31) | 69.24% (9) | 0.824 |
L0 | 34.05% (16) | 30.76% (4) | ||
Blood Vessel Invasion | V1 | 48.93% (23) | 61.53% (8) | 0.421 |
V0 | 51.07% (24) | 38.47% (5) | ||
Lymph Node Metastases | N1+ | 87.23% (41) | 61.53% (8) | 0.034 |
N0 | 12.76% (6) | 38.47% (5) | ||
Distant Metastases | M1 | 19.14% (9) | 23.08% (3) | 0.754 |
M0 | 80.86% (38) | 76.92% (10) | ||
MUC2 | Negative | 85.1% (40) | 69.24% (9) | 0.368 |
Positive | 14.9% (7) | 30.76% (4) | ||
MUC5AC | Negative | 61.7% (29) | 84.62% (11) | 0.049 |
Positive | 38.3% (18) | 15.38% (2) | ||
CDX2 | Negative | 76.6% (36) | 23.08% (3) | 0.405 |
Positive | 23.4% (11) | 76.92% (10) |
Immunohistochemical Marker | With Intestinal Metaplasia (n = 16) | Without Intestinal Metaplasia (n = 44) | p-Values | |
---|---|---|---|---|
VSIG1 | Negative | 62.5% (10) | 84.1% (37) | 0.046 |
Positive | 37.5% (6) | 15.9% (7) | ||
MUC2 | Negative | 62.5% (10) | 88.63% (39) | 0.02 |
Positive | 37.5% (6) | 11.37% (5) | ||
CDX2 | Negative | 25% (4) | 79.55% (35) | 0.0009 |
Positive | 75% (12) | 20.45% (9) | ||
MUC5AC | Negative | 68.75% (11) | 65.9% (29) | 0.836 |
Positive | 31.25% (5) | 34.1% (15) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Satala, C.-B.; Jung, I.; Gurzu, S. Mucin-Phenotype and Expression of the Protein V-Set and Immunoglobulin Domain Containing 1 (VSIG1): New Insights into Gastric Carcinogenesis. Int. J. Mol. Sci. 2023, 24, 8697. https://doi.org/10.3390/ijms24108697
Satala C-B, Jung I, Gurzu S. Mucin-Phenotype and Expression of the Protein V-Set and Immunoglobulin Domain Containing 1 (VSIG1): New Insights into Gastric Carcinogenesis. International Journal of Molecular Sciences. 2023; 24(10):8697. https://doi.org/10.3390/ijms24108697
Chicago/Turabian StyleSatala, Catalin-Bogdan, Ioan Jung, and Simona Gurzu. 2023. "Mucin-Phenotype and Expression of the Protein V-Set and Immunoglobulin Domain Containing 1 (VSIG1): New Insights into Gastric Carcinogenesis" International Journal of Molecular Sciences 24, no. 10: 8697. https://doi.org/10.3390/ijms24108697